Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer

Therapeutics: Dual therapy shrinks triple negative breast tumors Two experimental drugs currently in clinical trials as single agents might work better together against triple negative breast cancer. Jeffrey Solzak and Milan Radovich, and colleagues from the Indiana University School of Medicine in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jeffrey P. Solzak, Rutuja V. Atale, Bradley A. Hancock, Anthony L. Sinn, Karen E. Pollok, David R. Jones, Milan Radovich
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4e107a1dad504786a827e6d2492a7acf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e107a1dad504786a827e6d2492a7acf
record_format	dspace
spelling	oai:doaj.org-article:4e107a1dad504786a827e6d2492a7acf2021-12-02T12:30:15ZDual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer10.1038/s41523-017-0016-82374-4677https://doaj.org/article/4e107a1dad504786a827e6d2492a7acf2017-04-01T00:00:00Zhttps://doi.org/10.1038/s41523-017-0016-8https://doaj.org/toc/2374-4677Therapeutics: Dual therapy shrinks triple negative breast tumors Two experimental drugs currently in clinical trials as single agents might work better together against triple negative breast cancer. Jeffrey Solzak and Milan Radovich, and colleagues from the Indiana University School of Medicine in Indianapolis, USA, analyzed gene expression data from cancerous and healthy breast tissues and from published genomic datasets. They found the PI3K pathway consistently activated in the majority of breast cancers that test negative for the three most common receptors known to fuel breast tumor growth. Inhibiting PI3K in these cells led to a marked increase in the activity of another critical pathway called Wnt, an observation that prompted the researchers to test a combination of a PI3K inhibitor, buparlisib, and a Wnt inhibitor, WNT974, in cell lines and xenograft models. Tumor cells shrunk more and mice lived longer than treatment with either agent alone.Jeffrey P. SolzakRutuja V. AtaleBradley A. HancockAnthony L. SinnKaren E. PollokDavid R. JonesMilan RadovichNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 3, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jeffrey P. Solzak Rutuja V. Atale Bradley A. Hancock Anthony L. Sinn Karen E. Pollok David R. Jones Milan Radovich Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
description	Therapeutics: Dual therapy shrinks triple negative breast tumors Two experimental drugs currently in clinical trials as single agents might work better together against triple negative breast cancer. Jeffrey Solzak and Milan Radovich, and colleagues from the Indiana University School of Medicine in Indianapolis, USA, analyzed gene expression data from cancerous and healthy breast tissues and from published genomic datasets. They found the PI3K pathway consistently activated in the majority of breast cancers that test negative for the three most common receptors known to fuel breast tumor growth. Inhibiting PI3K in these cells led to a marked increase in the activity of another critical pathway called Wnt, an observation that prompted the researchers to test a combination of a PI3K inhibitor, buparlisib, and a Wnt inhibitor, WNT974, in cell lines and xenograft models. Tumor cells shrunk more and mice lived longer than treatment with either agent alone.
format	article
author	Jeffrey P. Solzak Rutuja V. Atale Bradley A. Hancock Anthony L. Sinn Karen E. Pollok David R. Jones Milan Radovich
author_facet	Jeffrey P. Solzak Rutuja V. Atale Bradley A. Hancock Anthony L. Sinn Karen E. Pollok David R. Jones Milan Radovich
author_sort	Jeffrey P. Solzak
title	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
title_short	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
title_full	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
title_fullStr	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
title_full_unstemmed	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
title_sort	dual pi3k and wnt pathway inhibition is a synergistic combination against triple negative breast cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/4e107a1dad504786a827e6d2492a7acf
work_keys_str_mv	AT jeffreypsolzak dualpi3kandwntpathwayinhibitionisasynergisticcombinationagainsttriplenegativebreastcancer AT rutujavatale dualpi3kandwntpathwayinhibitionisasynergisticcombinationagainsttriplenegativebreastcancer AT bradleyahancock dualpi3kandwntpathwayinhibitionisasynergisticcombinationagainsttriplenegativebreastcancer AT anthonylsinn dualpi3kandwntpathwayinhibitionisasynergisticcombinationagainsttriplenegativebreastcancer AT karenepollok dualpi3kandwntpathwayinhibitionisasynergisticcombinationagainsttriplenegativebreastcancer AT davidrjones dualpi3kandwntpathwayinhibitionisasynergisticcombinationagainsttriplenegativebreastcancer AT milanradovich dualpi3kandwntpathwayinhibitionisasynergisticcombinationagainsttriplenegativebreastcancer
_version_	1718394395628142592

Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer

Ejemplares similares